Alkermes — Third Quarter 2026 Earnings Summary

Alkermes plc reported third-quarter 2026 revenues of $480.1 million, driven by a 31% increase in proprietary net sales to $417.3 million. The company achieved a GAAP net income of $16.3 million and an adjusted EBITDA of $120.1 million for the quarter, while maintaining its full-year 2026 financial guidance. Key product performance included $127.6 million in VIVITROL sales, $103.9 million in ARISTADAi sales, and $89.9 million in LUMRYZ sales, with the latter reaching approximately 4,100 patients by quarter-end. Additionally, the company's cash, cash equivalents, and total investments rose to $787.6 million as of September 30, 2026.